Association between thrombophilic gene variants and thrombosis in the Iranian population: a systematic review and meta-analysis
Systematic review published in Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis (2025)
Abstract
Thrombophilia is influenced by genetic variants, such as Factor V Leiden (FVL) and the prothrombin G20210A mutation. In clinical settings, assessing numerous genetic factors can lead to diagnostic errors and unnecessary treatments. This meta-analysis examines gene variants associated with thrombosis in the Iranian population, where their role in thrombotic disorders remains underexplored. A systematic literature search was performed across PubMed, Scopus, and Web of Science, targeting case-control studies published up to July 2025. Studies were included if they evaluated thrombophilia-related polymorphisms in Iranian patients with various thrombotic conditions, such as recurrent pregnancy loss (RPL), venous thromboembolism (VTE), or deep vein thrombosis (DVT). Advanced statistical analyses, including random-effects models, fixed-effects models, and Bayesian meta-analysis, were used to compute odds ratios (ORs) and 95% confidence intervals (CIs). From 36 studies encompassing over 14 000 participants, significant associations emerged. For RPL, FVL G1691A heterozygote (OR: 1.998, 95% CI: 1.02-3.88), methylenetetrahydrofolate reductase (MTHFR) C677T heterozygote (OR: 1.77, 95% CI: 1.31-2.39), MTHFR A1298C heterozygote (OR: 3.10, 95% CI: 1.33-7.20) and homozygote (OR: 1.69, 95% CI: 1.05-2.70), prothrombin G20210A heterozygote (OR: 2.435, 95% CI: 1.09-5.39) and homozygote (OR: 0.487, 95% CI: 0.40-0.58), plasminogen activator inhibitor-1 (PAI-1) polymorphisms, factor V (FV) A4070G, FV 5279A/G, factor XIII (FXIII) Val34Leu, and integrin subunit beta-3 (ITGB3)1565T/C were linked to elevated RPL risk. Additionally, FVL G1691A heterozygote (OR: 5.25, 95% CI: 2.39-11.54) was associated with higher VTE risk, while MTHFR C677T heterozygote (OR: 1.404, 95% CI: 1.030-1.914) increased DVT risk. These ethnicity-specific findings highlight critical genetic risk factors for thrombotic disorders in Iranians, potentially guiding precise diagnostics and personalized interventions.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Thrombophilia is influenced by genetic variants, such as Factor V Leiden (FVL) and the prothrombin G20210A mutation. In clinical settings, assessing numerous genetic factors can lead to diagnostic errors and unnecessary treatments.
Warum dies für die Hirudotherapie relevant ist
Diese systematische Übersichtsarbeit und Metaanalyse von 36 Fall-Kontroll-Studien (über 14 000 Teilnehmer) quantifizierte, wie thrombophile Genvarianten — Factor V Leiden, Prothrombin G20210A, MTHFR, PAI-1 und andere — in der iranischen Bevölkerung mit wiederholtem Schwangerschaftsverlust, venöser Thromboembolie und tiefer Venenthrombose assoziiert sind, und berichtete für mehrere Varianten erhöhte Odds Ratios. Für ASH ist dies Hintergrundwissen darüber, wer ein ererbtes hyperkoagulables Risiko trägt — der Patientenkontext, in dem jede antithrombotische Strategie (pharmakologisch oder das natürliche antikoagulatorische Sekretom des Blutegels) erwogen wird. Ehrliche Einschränkung: Dies ist genetisch-epidemiologische Evidenz, die andere Studien in einer ethnischen Bevölkerung zusammenfasst, mit hoher Relevanz für die Risikostratifizierung von Thrombosen, aber ohne Relevanz für die Behandlung; sie sagt nichts über Hirudotherapie, Blutegel oder irgendeine therapeutische Intervention aus.
Zitation
Association between thrombophilic gene variants and thrombosis in the Iranian population: a systematic review and meta-analysis.
Safdari SM et al. · Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2025
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026